launch of the Early Access Cohort Study on Fosravuconazole at Kassala Mycetoma Research Satellite Centre

We’re proud to announce the launch of the Early Access Cohort Study on Fosravuconazole at our newly established Kassala Mycetoma Research Satellite Centre in Eastern Sudan! This groundbreaking initiative marks a key milestone in the fight against mycetoma, a devastating and neglected tropical disease that continues to impact vulnerable communities with limited access to diagnosis and treatment. The study is a result of a strategic and long-standing collaboration between the Mycetoma Research Centre (MRC), the Drugs for Neglected Diseases initiative (DNDi), and Eisai Co., Ltd. Together, we are working to accelerate access to Fosravuconazole, a promising investigational drug with potential to offer safer and more effective treatment options for patients suffering from this chronic condition. Our new Kassala Satellite Centre plays a vital role in expanding access to care, enabling local research capacity, and reaching more patients in endemic regions. The centre will also support ongoing community engagement, early diagnosis, and treatment monitoring — key elements in advancing mycetoma control and elimination efforts.  This partnership reflects what can be achieved through global collaboration, patient-centered research, and a shared vision of health equity. We look forward to sharing updates as the study progresses.